14.30 (-%)
As of Oct 31, 2024
Source:
Catalyst Biosciences, Inc., together with its subsidiary, is a biopharmaceutical company focused on the development and commercialization of Hydronidone for the treatment of NASH in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a broad spectrum of chronic liver diseases.
Country | United States |
Headquarters | south san francisco, california |
Phone Number | 650-871-0761 |
Industry | manufacturing |
CEO | Nassim Usman |
Website | www.catalystbiosciences.com |